N/A Completed N=56 Randomized Single-blind Treatment

Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients

Source: ClinicalTrials.gov NCT02924324 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2022

Primary outcomePrimary: Number of Participants Requiring Post-procedural Opioid Analgesia Per Study Arm — 22; 22; 34; 34 participants

Summary

The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The addition of this medicine, called ropivacaine, is the experimental part of this study. This is the first time ropivacaine will be directly injected into the bone marrow site at MSKCC Pediatrics.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Requiring Post-procedural Opioid Analgesia Per Study Arm	22; 22; 34; 34	—

Eligibility Criteria

Inclusion Criteria

Diagnosis of neuroblastoma as defined by the International Neuroblastoma Risk Group Staging System (INRGSS)22
3 - 18 years of age
Patient has had prior bone marrow procedures
English speaking

Exclusion Criteria

History of allergy to investigational agent: ropivacaine or other amino amide analgesics
History of allergy to standard agent: propofol
Chronic daily opioid requirement
Lansky/Karnofsky Score < 60
Inability to comply with protocol requirements including refusal to forego pre-procedural opioid use
Patient is receiving additional potentially painful interventions (e.g. central line insertion/removal) concurrent with the bone marrow procedure

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02924324). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.